In Reply We appreciate the letter written by Lopez-Candales and Vallurupalli about our article1 and agree that caution is indicated when interpreting a post hoc analysis with a small number of events. Lopez-Candales and Vallurupalli note that aortic valve replacement could have been for endocarditis or concomitant surgical coronary revascularization. While this is an important consideration, only patients with aortic valve replacements that appeared to be for aortic stenosis were included in the analyses, and endocarditis was not listed as an adverse event for any of these patients. Concomitant coronary artery bypass grafting is also quite relevant, although the results were consistent when 9 patients who experienced a major adverse cardiovascular event, including coronary revascularization, concurrent with or prior to the aortic valve replacement were removed.1
Bergmark BA, Sabatine MS. PCSK9 Inhibition—A Tale of 2 Potential Treatment Opportunities—Reply. JAMA Cardiol. 2021;6(4):481. doi:10.1001/jamacardio.2020.5613
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.